Voices
Shaheenah Dawood: Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
Shaheenah Dawood/LinkedIn

Shaheenah Dawood: Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors

Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:

“AXINET: Phase III in G1–2 epNETs (n=256)

  • Axitinib + oct LAR vs PBO + oct LAR
  • INV PFS 17.2 vs 13.1 mo
  • ORR 12.8% vs 3.2%”

Title: Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)

Authors: Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, Teresa Alonso-Gordoa, Alex Teulé, Ana Custodio, Salvatore Tafuto, Adelaida La Casta, Francesca Spada, Carlos López, Toni Ibrahim, Vega Iranzo, Pilar García-Alfonso, Encarna González-Flores, María José Villanueva Silva, Enrique Grande, Francesco Panzuto, Guillermo Crespo, Miguel Navarro, Daniel Castellano, Jorge Hernando, Rocío Morales-Herrero, German Iglesias Álvarez, Beatriz Soldevilla, Jaume Capdevila

Read the Full Article.

Shaheenah Dawood: Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors

Other articles featuring Shaheenah Dawood on OncoDaily.

Adelaida La Casta Alex Teule Ana Custodio Beatriz Soldevilla cancer Carlos Lopez Daniel Castellano Encarna González-Flores Enrique Grande Francesca Spada Francesco Panzuto German Iglesias Álvarez Guillermo Crespo Jaume Capdevila Jorge Hernando María José Villanueva Silva Marta Benavent Miguel Navarro OncoDaily Oncology Paula Jimenez-Fonseca Pilar García-Alfonso Rocio Garcia-Carbonero Rocío Morales-Herrero Salvatore Tafuto Shaheenah Dawood Teresa Alonso-Gordoa Toni Ibrahim Vega Iranzo